11th National Volume‑Based Procurement Launches, 55 Drugs Cut Prices to Benefit Patients

On May 25, 2026, the 11th National Centralized Drug Procurement results were fully implemented across public hospitals nationwide, covering 55 commonly used drugs in oncology, cardiovascular, diabetes, anti‑infectives and other areas.

Winning prices averaged a 54% reduction vs original listed prices, with many originator drugs cut by >60%, significantly reducing patient costs. The “volume‑for‑price” model preserves reasonable margins for manufacturers, achieving a triple win for patients, industry and payers.

Since 2026, procurement policy has shifted from “price pressure” to “stabilizing expectations and encouraging innovation”. Reimbursement access for innovative drugs has accelerated, with multiple recently approved Class 1 drugs quickly entering national reimbursement negotiations, improving access and supporting high‑quality industry growth.